Boston Scientific Corporation (BSX) EVP Timothy A. Pratt Sells 10,000 Shares

Boston Scientific Corporation (NYSE:BSX) EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific Corporation stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the sale, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at approximately $4,647,297.82. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm earned $0.27 EPS.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2017/11/02/boston-scientific-corporation-bsx-evp-timothy-a-pratt-sells-10000-shares.html.

BSX has been the subject of several research analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. UBS AG reaffirmed a “buy” rating and issued a $31.00 price objective (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 31st. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a report on Monday, July 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $30.77.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Securities Inc. grew its position in Boston Scientific Corporation by 0.9% during the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock worth $318,000 after purchasing an additional 99 shares during the period. ETRADE Capital Management LLC grew its position in Boston Scientific Corporation by 1.7% during the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock worth $279,000 after purchasing an additional 171 shares during the period. BB&T Corp grew its position in Boston Scientific Corporation by 2.8% during the 2nd quarter. BB&T Corp now owns 12,926 shares of the medical equipment provider’s stock worth $359,000 after purchasing an additional 349 shares during the period. Krilogy Financial LLC grew its position in Boston Scientific Corporation by 5.9% during the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 430 shares during the period. Finally, Wetherby Asset Management Inc. grew its position in Boston Scientific Corporation by 3.9% during the 2nd quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock worth $382,000 after purchasing an additional 523 shares during the period. 90.47% of the stock is currently owned by institutional investors.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit